


| Catalogue Number | Product | Order number / Unit |
|------------------|---|---|
| 9831 | DOTA-Lanreotide acetate Precursor for radiolabelled DOTA-Lanreotide Ligand for somatostatin receptors Molar Mass: 1481.7 $C_{70}H_{95}N_{15}O_{17}S_2$ [213187-44-1] (net peptide) Colourless to off-white freeze-dried solid packaged in screw cap vials. Purity: $\geq 95\%$ Certificates: CoA; MS (identity); HPLC (purity) Chemical Name: Sequence: DOTA-D-2-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH ₂ , cyclic disulfide DOTA = N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]- Supplied as acetate salt Synonyms: DOTA-BIM-23014; CA index name: L-Threoninamide, 3-(2-naphthalenyl)-N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-D-alanyl-L-cysteinyl-L-Tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2→7) disulfide Literature: Smith-Jones P.M. et al. DOTA-Lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. <i>Endocrinology</i> 1999, 140, 5136 - 5148. Banerjee S. et al. ¹⁷⁷ Lu-DOTA-lanreotide: a novel tracer as a targeted agent for tumor therapy. <i>Nucl. Med. Biol.</i> 2004, 31, 753-759. | 9831.0001: 1 mg per vial 9831.0010: 10 mg per vial Please inquire for customized filling and bulk quantities.  |

date of product catalogue issue: 10 May 2017